TL;DR: Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in Russia as an analog of the immunomodulatory tetrapeptide tuftsin. Preclinical research, largely from Russian institutions, has documented effects on GABAergic signaling, BDNF expression, enkephalin-degrading enzyme activity, and cytokine modulation in rodent and in vitro models. Selank is not FDA approved. It has been registered and studied in Russia. The overall evidence base is limited, concentrated in early-phase and non-English literature, and does not establish clinical safety or efficacy in humans.
Research-Use Disclaimer: This article is for educational and research reference purposes only. Selank is a research compound, not approved by the FDA for human use in the United States. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.
What Is Selank? Definition, Structure, and Origins
Selank, also designated TP-7 in earlier literature, is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structurally modified analog of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) naturally cleaved from immunoglobulin G and known for its role in stimulating macrophage activity and immune function.
The design rationale documented in the research literature centers on a key limitation of native tuftsin: rapid enzymatic degradation. Researchers extended the tuftsin sequence with the tripeptide Pro-Gly-Pro, a fragment also found in collagen and studied for its own CNS-modulating properties, to yield a compound with greater metabolic stability and prolonged biological activity. The resulting heptapeptide was reported in early studies to retain tuftsin’s immunomodulatory properties while acquiring anxiolytic and nootropic-like effects in rodent behavioral models.
What Mechanisms Has Selank Research Documented?
Selank’s documented mechanistic profile spans several biological pathways, which is consistent with its structural derivation from tuftsin, a pleiotropic immunomodulatory peptide. The mechanisms described below are drawn from published preclinical research; they represent observed associations in experimental models, not established clinical mechanisms of action.
1. GABAergic Signaling: Positive Allosteric Modulation
One of the most directly studied molecular mechanisms of Selank involves its interaction with the GABA receptor system. A 2018 study by Vyunova et al. published in Protein and Peptide Letters used radioligand-receptor analysis to investigate Selank’s binding behavior at GABA receptors in rat brain membrane preparations. The study documented that Selank modulated [³H]GABA binding as a positive allosteric modulator in a subtype-selective, concentration-dependent manner, and further showed that the joint action of Selank with benzodiazepines (diazepam and olanzapine) was non-cumulative and distinct from either substance alone, suggesting partially overlapping but non-identical binding sites. The investigators proposed positive allosteric modulation of GABA-A receptors as one of Selank’s anti-anxiety molecular mechanisms.
Consistent with this GABAergic hypothesis, a 2017 study by Kasian et al. in Behavioural Neurology examined Selank and diazepam separately and in combination in Wistar rats under unpredictable chronic mild stress conditions using the elevated plus maze test. The study found that individual administration of Selank was most effective in reducing anxiety induced by chronic compound administration, while combined Selank-diazepam treatment was most effective in reducing anxiety under chronic stress conditions, a finding the authors interpreted as consistent with a shared but not fully overlapping mechanism with classical benzodiazepines.
2. BDNF Expression in the Hippocampus
Brain-derived neurotrophic factor (BDNF) is a neurotrophin with documented roles in synaptic plasticity, learning, and memory consolidation. Selank’s documented relationship with BDNF has been examined in both acute and chronic experimental contexts.
A 2008 study by Inozemtseva et al., published in Doklady Biological Sciences, administered Selank intranasally to male Wistar rats and used RT-PCR and immunoenzymatic assay to measure BDNF mRNA and protein levels in the hippocampus in vivo. The study documented that intranasal administration of Selank produced changes in hippocampal BDNF expression, providing an early in vivo evidence point for neurotrophin involvement in Selank’s observed effects.
This BDNF-modulating effect was extended in a 2019 study by Kolik et al. in the Bulletin of Experimental Biology and Medicine, which evaluated Selank in rats exposed to chronic ethanol (10% solution as the sole fluid source for 30 weeks). Selank (0.3 mg/kg/day, 7 days, intraperitoneally) prevented ethanol-induced increases in BDNF content in the hippocampus and frontal cortex, and produced a cognitive-stimulating effect on the object recognition test in animals not exposed to ethanol. The authors concluded that neurotrophin mechanisms related to BDNF production are involved in Selank’s observed cognitive effects in this rodent model.
3. Enkephalin-Degrading Enzyme Activity
Tuftsin and its analogs have been studied in relation to peptidase activity, particularly enkephalin-degrading enzymes. Enkephalins are endogenous opioid pentapeptides involved in pain modulation, stress responses, and mood regulation. Research into Selank’s structural fragments has documented interactions with peptidase systems that regulate enkephalin half-life, a mechanism that has been proposed as one route through which Selank may extend the functional duration of endogenous opioid signaling in preclinical models.
The importance of Selank’s metabolic stability relative to native tuftsin was highlighted in studies identifying the Pro-Gly-Pro extension as critical for prolonged in vivo activity, as the native tuftsin sequence is rapidly cleaved by serum enzymes. A 2010 study by Andreeva et al. in Doklady Biological Sciences examined the antiviral properties of Selank’s structural fragments, isolating Gly-Pro as a pharmacophoric fragment with documented biological activity, which is consistent with the broader understanding that Selank’s metabolic breakdown products themselves may retain bioactivity and interact with peptidase systems.
4. Immunomodulation: Cytokine and Chemokine Gene Expression
Reflecting its structural derivation from tuftsin, Selank has been studied for immunomodulatory effects distinct from its behavioral profile. A 2011 study by Kolomin et al. in the Russian-language journal Genetika administered Selank and its fragments to mice and measured mRNA levels of chemokines, cytokines, and their receptors in the spleen at 6 and 24 hours post-administration. The study documented significant changes in the expression of the genes under study following Selank and its minimum active fragment (Gly-Pro) administration, supporting an immunomodulatory mechanism consistent with the tuftsin pharmacological profile and distinct from the GABAergic anxiolytic mechanism.
5. Anxiolytic-Like and Cognitive Behavioral Effects in Rodent Models
The largest body of Selank preclinical research involves behavioral testing in rodent anxiety and cognitive models. A 2003 study by Kozlovskii and Danchev in Neuroscience and Behavioral Physiology evaluated Selank (300 µg/kg) versus piracetam (400 mg/kg) using a conditioned active avoidance reflex paradigm in Wistar rats stratified by initial learning ability. Selank significantly activated learning in rats with initially poor performance, with progressive improvement across repeated administration days; the authors compared its nootropic-like dynamic profile favorably to piracetam in this model.
A 2006 study by Czabak-Garbacz et al. in Pharmacological Reports examined long-term Selank (TP-7) administration in Wistar rats with high initial emotional reactivity using Rodina’s behavioral method. Selank significantly reduced anxiety-phobic-like behavior from the second day of administration, with effects persisting across four weeks of the experiment and without producing changes in body weight, which the authors noted as consistent with an anxioselective profile.
In addiction-model contexts, a 2022 study by Konstantinopolsky et al. in the Bulletin of Experimental Biology and Medicine evaluated Selank in a naloxone-precipitated morphine withdrawal model in rats. A single intraperitoneal injection of Selank (0.3 mg/kg) reduced the total withdrawal syndrome index by approximately 40%, attenuated convulsive reactions and posture disorders, and increased tactile sensitivity threshold in morphine-dependent rats, with effects described as slightly inferior to, but comparable in direction to, diazepam (2 mg/kg).
What Is Selank’s Evidence Tier? An Honest Assessment
The evidence base for Selank has notable structural limitations that should be stated plainly for any researcher reviewing this compound.
| Evidence Level | Status for Selank (as of 2026) |
|---|---|
| Human randomized controlled trials (Western, peer-reviewed) | Not identified in the international PubMed-indexed literature as of this writing |
| Early-phase human research (Russian registration studies) | Referenced in the literature as having occurred; Selank is registered in Russia as a nasal anxiolytic, primary data not widely available in English |
| Peer-reviewed preclinical rodent studies | Present, multiple behavioral, biochemical, and morphological studies; predominantly from Russian institutions |
| Mechanistic in vitro evidence | Present for GABAergic modulation (radioligand studies) and gene expression studies |
| Independent international replication | Limited, much of the literature originates from a small set of overlapping Russian laboratories |
| FDA approval status (USA) | Not approved for any human use |
The critical limitation to state plainly: the concentration of Selank’s published research within a small set of Russian laboratories, primarily the V. V. Zakusov Research Institute of Pharmacology and the Institute of Molecular Genetics, Russian Academy of Sciences, limits what independent replication can be claimed. This is not evidence of fraud, but it is a significant epistemic limitation. Furthermore, rodent behavioral models of anxiety-like behavior do not reliably translate to human clinical outcomes. The research is scientifically interesting and mechanistically coherent, but the honest evidence tier is low by international standards.
What Is Selank’s Regulatory Status?
United States (FDA)
Selank is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no authorized human therapeutic indication, no approved dosing protocol, and is classified as a research compound in the United States. Researchers should consult current FDA guidance directly.
Russia
Selank has been registered in Russia as a pharmaceutical drug (nasal drops formulation) for use as an anxiolytic. This registration reflects the regulatory framework of the Russian Ministry of Health and does not confer approval status in the United States, European Union, or other Western regulatory jurisdictions. Russian registration studies exist but are not widely accessible in the English-language literature.
Frequently Asked Questions About Selank
What is Selank?
Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in Russia as an analog of the endogenous immunomodulatory tetrapeptide tuftsin. It was designed with an extended Pro-Gly-Pro tail to improve metabolic stability relative to native tuftsin. It has been studied in preclinical rodent models for anxiolytic-like activity, cognitive behavioral effects, BDNF modulation, and immunomodulatory properties.
Is Selank FDA approved?
No. Selank is not approved by the FDA for any therapeutic use in humans. It has been registered and studied in Russia, where a nasal formulation is approved as an anxiolytic drug. In the United States, it has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement.
How does Selank work, according to research?
Based on preclinical studies, Selank has been documented to act as a positive allosteric modulator of GABA receptors in rat brain membrane preparations, to regulate BDNF expression in the rat hippocampus following intranasal administration, and to influence cytokine and chemokine gene expression in mouse models consistent with immunomodulatory activity inherited from its tuftsin parent structure. These are observed research associations, not established clinical mechanisms, and have not been confirmed in large-scale human trials.
What is Selank’s evidence tier?
Selank is a Tier 2–3 compound in the Legendary Labz framework: a meaningful body of preclinical rodent and in vitro research exists, and limited early-phase human-use data from Russia is referenced in the literature. However, large placebo-controlled international RCTs are absent, independent replication outside Russian institutions is limited, and much of the primary data is in Russian-language sources with restricted international accessibility. Full evidence-tier methodology is documented in the guide.
Research use only. Not intended for human use. Not FDA approved. Selank has been studied and registered in Russia; it is not approved for human therapeutic use in the United States. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.